J. Camerlo

发表

Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy

F. Bertucci, B. Loriod, C. Nguyen, 2004, Cancer Research.

Breast cancer guidelines—Physicians' intentions and behaviors

V. Bardou, J. Camerlo, F. Eisinger, 2006, International journal of cancer.

Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy

P. Viens, C. Protière, D. Maraninchi, 2002, Supportive Care in Cancer.

Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care.

P. Viens, G. Gravis, D. Maraninchi, 1997, British Journal of Cancer.

Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma

P. Viens, J. Moatti, G. Gravis, 1999, Cancer.

Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy

R. Bouabdallah, V. Bardou, J. Pasquier, 2001, European Journal of Nuclear Medicine.

Intensive Sequential Chemotherapy for Untreated Poor-Risk Non-Hodgkin’s Lymphoma

J. Rossi, R. Bouabdallah, D. Blaise, 1998 .

Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: impact of length of cycles

P. Viens, G. Gravis, C. Protière, 2002, Supportive Care in Cancer.

High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer

F. Bertucci, D. Cowen, P. Viens, 1997, Bone Marrow Transplantation.

Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy.

J. Gabert, C. Arnoulet, D. Maraninchi, 1995, Leukemia & lymphoma.

PCR‐mismatch analysis of p53 gene mutation in Hodgkin's disease

R. Bouabdallah, L. Xerri, J. Hassoun, 1995, The Journal of pathology.

Simultaneous Occurrence of Kaposi's Sarcoma and Chronic Myelogenous Leukemia

L. Xerri, N. Vey, D. Maraninchi, 2001, Leukemia & lymphoma.

Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery.

R. Bouabdallah, D. Blaise, P. Viens, 1996, Journal of hematotherapy.

Repeated high-dose-melphalan with autologous bone marrow transplantation in acute non lymphocytic leukemia.

D. Maraninchi, G. Lepeu, J. Camerlo, 1985, Revue francaise de transfusion et immuno-hematologie.

Minor breakpoint cluster region (m‐BCR) positive chronic myeloid leukaemia with an acute lymphoblastic leukaemia onset: a case report

R. Bouabdallah, J. Gabert, C. Arnoulet, 1995, British journal of haematology.

Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens

F. Bertucci, P. Viens, C. Chabannon, 2002, Bone Marrow Transplantation.

High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study.

K. Cornetta, D. Blaise, M. Shlomchik, 1998, British Journal of Cancer.

Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.

P. Viens, G. Gravis, J. Ciccolini, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involvement.

R. Bouabdallah, D. Blaise, N. Vey, 1999, Hematology and cell therapy.

Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level

R. Bouabdallah, D. Blaise, M. Mohty, 2004, Transfusion.

Treatment of malignant lymphoma with high dose of chemo or chemoradiotherapy and bone marrow transplantation.

D. Maraninchi, D. Sainty, J. Camerlo, 1986, European journal of cancer & clinical oncology.

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.

François Bertucci, Mario Campone, F. Bertucci, 2017, European journal of cancer.

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

G. Serment, F. Bladou, V. Bardou, 2003, Cancer.

Docetaxel and Radiotherapy and Pancreatic Cancer

M. Ychou, P. Viens, G. Gravis, 2003, Pancreas.

Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution.

R. Bouabdallah, D. Blaise, P. Viens, 1998, Leukemia & lymphoma.

Association of angiogenesis and poor prognosis in node‐positive patients receiving anthracycline‐based adjuvant chemotherapy

F. Bertucci, F. Penault-Llorca, V. Bardou, 1999, Breast Cancer Research and Treatment.

Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation

R. Bouabdallah, B. Esterni, D. Blaise, 2005, Bone Marrow Transplantation.

Cost–effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation

D. Blaise, P. Viens, N. Vey, 2003, Leukemia.

Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients.

D. Olive, J. Gabert, D. Blaise, 1991, Bone marrow transplantation.

Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.

R. Bouabdallah, L. Xerri, D. Blaise, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery.

R. Bouabdallah, P. Viens, N. Vey, 1994, Bone marrow transplantation.

Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation.

D. Blaise, P. Viens, J. Moatti, 1998, Bone marrow transplantation.

Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: absence of eradication of the PNH clone and dependence of response on cyclosporin A administration

C. Arnoulet, N. Vey, D. Sainty, 1996, British journal of haematology.

Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data.

R. Bouabdallah, L. Xerri, J. Hassoun, 1994, Human pathology.

A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies.

R. Bouabdallah, D. Blaise, N. Vey, 1996, Bone marrow transplantation.

The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute’s Experience

D. Blaise, P. Viens, N. Vey, 2021, Clinical hematology international.

Full access to medical records does not modify anxiety in cancer patients

P. Viens, D. Coso, G. Gravis, 2011, Cancer.

Patient participation in medical decision-making: a French study in adjuvant radio-chemotherapy for early breast cancer.

F. Bertucci, D. Cowen, P. Viens, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of a combination of low-dose cisplatin with 13-cis-retinoic acid and interferon-alpha in patients with advanced head and neck squamous cell carcinoma.

P. Viens, G. Gravis, C. Alzieu, 1999, Anti-cancer drugs.

Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.

G. Serment, F. Bladou, D. Cowen, 1996, European cytokine network.

Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation

F. Bertucci, P. Viens, G. Houvenaeghel, 2002, Bone Marrow Transplantation.

Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patients.

D. Olive, D. Blaise, P. Viens, 1999, Journal of immunotherapy.

Chemotherapy Inflammatory Breast Cancer and Prediction of Response to Gene Expression Profiling for Molecular Characterization of Updated

F. Bertucci, B. Loriod, C. Nguyen, 2004 .

Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics.

F. Bertucci, P. Viens, G. Gravis, 2001, Anticancer research.

Full access to medical records does not modify anxiety in cancer patients

P. Viens, D. Coso, G. Gravis, 2011, Cancer.

Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamide.

J. Blache, D. Blaise, P. Viens, 1999, International journal of oncology.